Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation listed on the Nasdaq Capital Market, filed this Current Report on Form 8-K on August 10, 2023. The filing serves to announce the company's financial results for the period ended June 30, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. The document solely confirms the reporting of results for the period ended June 30, 2023, without detailing the variance from previous periods.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 10, 2023) for actual financial figures and operational highlights.
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2023, as they are not present in the 8-K cover text.
- Check the company's cash position and runway details in the full press release or accompanying 10-Q filing.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full report.